We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ViiV Healthcare’s Triumeq for HIV Gets CHMP Nod

ViiV Healthcare’s Triumeq for HIV Gets CHMP Nod

July 3, 2014

Drugmaker ViiV Healthcare has moved one step closer to launching its investigational HIV combination therapy Triumeq in Europe.

The EMA’s Committee for Medicinal Products for Human Use recommended Triumeq (dolutegravir/abacavir/lamivudine) for treatment of HIV in patients ages 12 and up who weigh at least 88 pounds. The recommendation now goes before the European Commission, where a marketing authorization decision is expected in the third quarter of 2014.

Two elements of the combo drug — lamivudine and abacavir — have been on the market since 1995 and 2004, respectively. Dolutegravir received FDA approved last August, followed by the EMA in January. Abacavir and lamivudine are reverse transcriptase inhibitors that block the transcription of HIV RNA into DNA, while the integrase-inhibitor dolutegravir works by blocking the processes through which viral DNA integrates itself into human CD4 immune cells.

If approved, Triumeq would join a handful of other once-daily HIV therapies, including Gilead Sciences’ Complera (rilpivirine/tenofovir/emtricitabine) and Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) and Truvada (emtricitabine/tenofovir disoproxil fumarate).

It is critical to offer doctors and patients treatment options that reduce the likelihood of drug resistance and/or discontinuation due to problems with tolerability, side effects and pill burden/dosing frequency, ViiV spokesman Marc Meacham said.

ViiV, which was created by GSK, Pfizer and Shionogi specifically to develop HIV drugs, submitted an NDA for Triumeq to the FDA in October 2013. That application is still under review. — Lena Freund

Originally appeared in Drug Industry Daily, the pharmaceutical industry’s number one source for regulatory news and information. Click here for more information.

Pharmaceuticals Submissions and Approvals

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing